---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-002493"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:08:59.397305+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Moleculin terminates $50M ATM equity agreement with Oppenheimer; no shares ever sold

## Summary
- Delivered termination notice to Oppenheimer on Feb 3, 2023; effective Feb 13, 2023.
- ATM agreement dated June 25, 2021 allowed up to $50M in common stock sales.
- No shares were sold under the ATM agreement during its entire term.
- Termination was at-will and without penalty per Section 13(b) of the agreement.

## SEC filing metadata
- accession: 0001437749-23-002493
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923002493/0001437749-23-002493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923002493/mbrx20230203_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-002493
- JSON: https://secwatch.observer/filing/0001437749-23-002493.json
- Plain text: https://secwatch.observer/filing/0001437749-23-002493.txt

## Key facts
- Material Agreements
  Moleculin Biotech, Inc. terminated At Market Issuance Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-02-03).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Oppenheimer & Co. Inc.
  - Value: up to $50,000,000
  - Effective: 2023-02-03
  source text: On February 3, 2023, Moleculin Biotech, Inc. (“Company”) delivered written notice to Oppenheimer & Co. Inc. (the “Agent”) that it was terminating its At Market Issuance Sales Agreement, dated June 25, 2021 (the “ATM Agreement”), pursuant to Section 13(b) of the ATM Agreement, effective on February 13, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923002493/0001437749-23-002493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.